Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics PLC (NASDAQ:ITRM) was the recipient of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 3,065,983 shares, a growth of 49.9% from the February 26th total of 2,045,972 shares. Currently, 5.9% of the shares of the company are short sold. Based on an average daily trading volume, of 2,768,177 shares, the short-interest ratio is presently 1.1 days.

Hedge Funds Weigh In On Iterum Therapeutics

Several hedge funds have recently bought and sold shares of the company. Apollon Financial LLC boosted its position in shares of Iterum Therapeutics by 151.8% during the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock worth $211,000 after acquiring an additional 380,000 shares in the last quarter. Jane Street Group LLC raised its position in Iterum Therapeutics by 1,893.5% during the fourth quarter. Jane Street Group LLC now owns 289,410 shares of the company’s stock valued at $97,000 after purchasing an additional 274,892 shares in the last quarter. Alchemi Wealth LLC bought a new stake in Iterum Therapeutics during the fourth quarter worth $90,000. Virtu Financial LLC bought a new stake in Iterum Therapeutics during the third quarter worth $32,000. Finally, OneDigital Investment Advisors LLC boosted its holdings in shares of Iterum Therapeutics by 18.6% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after purchasing an additional 30,000 shares in the last quarter. 9.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ITRM shares. Maxim Group downgraded Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Iterum Therapeutics in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Iterum Therapeutics has a consensus rating of “Hold” and an average price target of $9.00.

Iterum Therapeutics Stock Performance

Shares of NASDAQ ITRM traded down $0.14 during mid-day trading on Friday, reaching $0.04. The company had a trading volume of 70,752,790 shares, compared to its average volume of 1,613,413. Iterum Therapeutics has a one year low of $0.03 and a one year high of $1.42. The firm has a market cap of $1.90 million, a price-to-earnings ratio of -0.05 and a beta of 2.96. The business’s 50-day simple moving average is $0.24 and its 200 day simple moving average is $0.43.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).